(0.00%) 5 478.25 points
(-0.04%) 38 804 points
(0.05%) 19 931 points
(0.27%) $80.55
(1.18%) $2.82
(0.17%) $2 333.00
(-0.28%) $29.31
(-0.12%) $969.70
(0.02%) $0.932
(-0.14%) $10.64
(0.07%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer...
Stats | |
---|---|
Šios dienos apimtis | 1.59M |
Vidutinė apimtis | 6.64M |
Rinkos kapitalizacija | 106.75M |
EPS | $0.170 ( Q1 | 2024-05-08 ) |
Kita pelno data | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
6.52 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00500 (0.36%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-12 | Ogden Christopher | Buy | 17 500 | Common Stock |
2024-06-12 | Ogden Christopher | Buy | 75 000 | Stock Option (Right to Buy) |
2024-05-15 | Young Matthew P. | Buy | 38 000 | Stock Option (Right to Buy) |
2024-05-15 | Su Zhen | Buy | 38 000 | Stock Option (Right to Buy) |
2024-05-15 | Mohindru Mani | Buy | 38 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
67.89 |
Last 98 transactions |
Buy: 4 522 928 | Sell: 1 092 240 |
Tūris Koreliacija
CytomX Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
LOGC | 0.91 |
NALFX | 0.894 |
BWIN | 0.893 |
IIXIX | 0.892 |
RGSVX | 0.888 |
RGIVX | 0.888 |
ANTUX | 0.887 |
PGJZX | 0.883 |
INFR | 0.879 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
PLTNU | -0.886 |
LDWY | -0.847 |
AAPD | -0.83 |
BRLSW | -0.828 |
CGON | -0.818 |
PXMD | -0.812 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
CytomX Therapeutics Inc Koreliacija - Valiuta/Žaliavos
CytomX Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $101.21M |
Bruto pelnas: | $99.04M (97.85 %) |
EPS: | $-0.00770 |
FY | 2023 |
Pajamos: | $101.21M |
Bruto pelnas: | $99.04M (97.85 %) |
EPS: | $-0.00770 |
FY | 2022 |
Pajamos: | $53.16M |
Bruto pelnas: | $47.31M (88.98 %) |
EPS: | $-1.480 |
FY | 2021 |
Pajamos: | $69.57M |
Bruto pelnas: | $69.57M (100.00 %) |
EPS: | $-1.300 |
Financial Reports:
Symbol | Period | Year | Title |
---|---|---|---|
CTMX | Q1 | 2024 | Q1 2024 Financial Performance Analysis of CytomX Therapeutics Inc. |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.